Garenoxacin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Garenoxacin
Accession Number
DB06160
Type
Small Molecule
Groups
Investigational
Description

Garenoxacin (INN) is a quinolone antibiotic undergoing regulatory review for the treatment of gram-positive and gram-negative bacterial infections. [Wikipedia]

Structure
Thumb
Synonyms
  • desquinolone
External IDs
T-3811
Product Ingredients
IngredientUNIICASInChI Key
Garenoxacin MesylateOXI6EF55FR223652-90-2IGTHEWGRXUAFKF-NVJADKKVSA-N
Categories
UNII
V72H9867WB
CAS number
194804-75-6
Weight
Average: 426.42
Monoisotopic: 426.139113458
Chemical Formula
C23H20F2N2O4
InChI Key
NJDRXTDGYFKORP-LLVKDONJSA-N
InChI
InChI=1S/C23H20F2N2O4/c1-11-15-5-2-12(8-13(15)9-26-11)16-6-7-17-19(21(16)31-23(24)25)27(14-3-4-14)10-18(20(17)28)22(29)30/h2,5-8,10-11,14,23,26H,3-4,9H2,1H3,(H,29,30)/t11-/m1/s1
IUPAC Name
1-cyclopropyl-8-(difluoromethoxy)-7-[(1R)-1-methyl-2,3-dihydro-1H-isoindol-5-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
SMILES
C[[email protected]]1NCC2=CC(=CC=C12)C1=CC=C2C(=O)C(=CN(C3CC3)C2=C1OC(F)F)C(O)=O

Pharmacology

Indication

Investigated for use/treatment in bacterial infection.

Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Garenoxacin.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Garenoxacin.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Garenoxacin.Experimental, Illicit
AceclofenacAceclofenac may increase the neuroexcitatory activities of Garenoxacin.Approved, Investigational
AcemetacinAcemetacin may increase the neuroexcitatory activities of Garenoxacin.Approved, Experimental, Investigational
AcenocoumarolGarenoxacin may increase the anticoagulant activities of Acenocoumarol.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Garenoxacin.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Garenoxacin.Experimental
Acetylsalicylic acidAcetylsalicylic acid may increase the neuroexcitatory activities of Garenoxacin.Approved, Vet Approved
AdapaleneAdapalene may increase the neuroexcitatory activities of Garenoxacin.Approved
AlclofenacAlclofenac may increase the neuroexcitatory activities of Garenoxacin.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Garenoxacin.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Garenoxacin.Experimental, Investigational
AlmasilateAlmasilate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
AlminoprofenAlminoprofen may increase the neuroexcitatory activities of Garenoxacin.Experimental
AloglutamolAloglutamol can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
AluminiumAluminium can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Aluminium acetoacetateAluminium acetoacetate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminium glycinateAluminium glycinate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ambroxol acefyllinateThe metabolism of Ambroxol acefyllinate can be decreased when combined with Garenoxacin.Experimental, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Garenoxacin.Approved
AncestimThe risk or severity of cytotoxicity can be increased when Ancestim is combined with Garenoxacin.Approved, Investigational, Withdrawn
AndrographolideAndrographolide may increase the neuroexcitatory activities of Garenoxacin.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Androstenedione is combined with Garenoxacin.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Anecortave is combined with Garenoxacin.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Garenoxacin.Investigational
AnisodamineAnisodamine may increase the neuroexcitatory activities of Garenoxacin.Investigational
AntipyrineAntipyrine may increase the neuroexcitatory activities of Garenoxacin.Approved
ApocyninApocynin may increase the neuroexcitatory activities of Garenoxacin.Investigational
ApremilastApremilast may increase the neuroexcitatory activities of Garenoxacin.Approved, Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Atamestane is combined with Garenoxacin.Investigational
AzapropazoneAzapropazone may increase the neuroexcitatory activities of Garenoxacin.Withdrawn
AzelastineAzelastine may increase the neuroexcitatory activities of Garenoxacin.Approved
BalsalazideBalsalazide may increase the neuroexcitatory activities of Garenoxacin.Approved, Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Garenoxacin.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Garenoxacin.Approved, Investigational
BendazacBendazac may increase the neuroexcitatory activities of Garenoxacin.Experimental
BenorilateBenorilate may increase the neuroexcitatory activities of Garenoxacin.Experimental
BenoxaprofenBenoxaprofen may increase the neuroexcitatory activities of Garenoxacin.Withdrawn
BenzydamineBenzydamine may increase the neuroexcitatory activities of Garenoxacin.Approved
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Garenoxacin.Approved, Vet Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Garenoxacin.Approved, Investigational
BevoniumBevonium may increase the neuroexcitatory activities of Garenoxacin.Experimental
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Bismuth subnitrateBismuth subnitrate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
BromfenacBromfenac may increase the neuroexcitatory activities of Garenoxacin.Approved
BucillamineBucillamine may increase the neuroexcitatory activities of Garenoxacin.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Garenoxacin.Approved
BufexamacBufexamac may increase the neuroexcitatory activities of Garenoxacin.Experimental
BumadizoneBumadizone may increase the neuroexcitatory activities of Garenoxacin.Experimental
Calcium AcetateCalcium Acetate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium CarbonateCalcium Carbonate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium ChlorideCalcium Chloride can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium CitrateCalcium Citrate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium glubionateCalcium glubionate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium GluceptateCalcium Gluceptate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium gluconateCalcium gluconate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Calcium lactateCalcium lactate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental, Investigational, Vet Approved
Calcium lactate gluconateCalcium lactate gluconate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Calcium levulinateCalcium laevulate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Calcium pangamateCalcium pangamate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Calcium PhosphateCalcium Phosphate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium silicateCalcium silicate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Carbaspirin calciumCarbaspirin calcium may increase the neuroexcitatory activities of Garenoxacin.Experimental, Investigational
CarprofenCarprofen may increase the neuroexcitatory activities of Garenoxacin.Approved, Vet Approved, Withdrawn
CaseinCasein can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CastanospermineCastanospermine may increase the neuroexcitatory activities of Garenoxacin.Experimental
CelecoxibCelecoxib may increase the neuroexcitatory activities of Garenoxacin.Approved, Investigational
ChloroquineChloroquine may increase the neuroexcitatory activities of Garenoxacin.Approved, Vet Approved
Choline magnesium trisalicylateCholine magnesium trisalicylate may increase the neuroexcitatory activities of Garenoxacin.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Garenoxacin.Approved, Investigational
ClobetasolThe risk or severity of adverse effects can be increased when Clobetasol is combined with Garenoxacin.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Garenoxacin.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Clobetasone is combined with Garenoxacin.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Garenoxacin.Approved
ClonixinClonixin may increase the neuroexcitatory activities of Garenoxacin.Approved
ClorindioneGarenoxacin may increase the anticoagulant activities of Clorindione.Experimental
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Cortexolone 17α-propionate is combined with Garenoxacin.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Corticosterone is combined with Garenoxacin.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Garenoxacin.Approved
CurcuminCurcumin may increase the neuroexcitatory activities of Garenoxacin.Investigational
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Garenoxacin.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Garenoxacin.Experimental
DeflazacortThe risk or severity of adverse effects can be increased when Deflazacort is combined with Garenoxacin.Approved, Investigational
DeslanosideDeslanoside may decrease the cardiotoxic activities of Garenoxacin.Approved
DesonideThe risk or severity of adverse effects can be increased when Desonide is combined with Garenoxacin.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Garenoxacin.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Garenoxacin.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Garenoxacin.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Garenoxacin.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Garenoxacin.Vet Approved
DiclofenacDiclofenac may increase the neuroexcitatory activities of Garenoxacin.Approved, Vet Approved
DicoumarolGarenoxacin may increase the anticoagulant activities of Dicoumarol.Approved
DidanosineThe serum concentration of Didanosine can be decreased when it is combined with Garenoxacin.Approved
DifenpiramideDifenpiramide may increase the neuroexcitatory activities of Garenoxacin.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Garenoxacin.Approved
DiflunisalDiflunisal may increase the neuroexcitatory activities of Garenoxacin.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Garenoxacin.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Garenoxacin.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Garenoxacin.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Garenoxacin.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Garenoxacin.Approved
DiphenadioneGarenoxacin may increase the anticoagulant activities of Diphenadione.Experimental
DroxicamDroxicam may increase the neuroexcitatory activities of Garenoxacin.Withdrawn
DuvelisibDuvelisib may increase the neuroexcitatory activities of Garenoxacin.Investigational
E-6201E-6201 may increase the neuroexcitatory activities of Garenoxacin.Investigational
EpirizoleEpirizole may increase the neuroexcitatory activities of Garenoxacin.Approved
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Garenoxacin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Garenoxacin.Approved
EstroneThe risk or severity of adverse effects can be increased when Estrone is combined with Garenoxacin.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Garenoxacin.Approved
EtanerceptEtanercept may increase the neuroexcitatory activities of Garenoxacin.Approved, Investigational
EthenzamideEthenzamide may increase the neuroexcitatory activities of Garenoxacin.Experimental
Ethyl biscoumacetateGarenoxacin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtodolacEtodolac may increase the neuroexcitatory activities of Garenoxacin.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the neuroexcitatory activities of Garenoxacin.Approved, Investigational
EtoricoxibEtoricoxib may increase the neuroexcitatory activities of Garenoxacin.Approved, Investigational
Evening primrose oilEvening primrose oil may increase the neuroexcitatory activities of Garenoxacin.Approved, Investigational
ExisulindExisulind may increase the neuroexcitatory activities of Garenoxacin.Investigational
FelbinacFelbinac may increase the neuroexcitatory activities of Garenoxacin.Experimental
FenbufenFenbufen may increase the neuroexcitatory activities of Garenoxacin.Approved
FenoprofenFenoprofen may increase the neuroexcitatory activities of Garenoxacin.Approved
FentiazacFentiazac may increase the neuroexcitatory activities of Garenoxacin.Experimental
FeprazoneFeprazone may increase the neuroexcitatory activities of Garenoxacin.Experimental
Ferulic acidFerulic acid may increase the neuroexcitatory activities of Garenoxacin.Experimental
FloctafenineFloctafenine may increase the neuroexcitatory activities of Garenoxacin.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Fluasterone is combined with Garenoxacin.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Garenoxacin.Approved
FluindioneGarenoxacin may increase the anticoagulant activities of Fluindione.Investigational
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Garenoxacin.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with Garenoxacin.Approved, Investigational
FlunixinFlunixin may increase the neuroexcitatory activities of Garenoxacin.Vet Approved
FlunoxaprofenFlunoxaprofen may increase the neuroexcitatory activities of Garenoxacin.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Garenoxacin.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Garenoxacin.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Garenoxacin.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Garenoxacin.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Garenoxacin.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Garenoxacin.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Garenoxacin.Approved
FlurbiprofenFlurbiprofen may increase the neuroexcitatory activities of Garenoxacin.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Garenoxacin.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Garenoxacin.Approved
FormestaneThe risk or severity of adverse effects can be increased when Formestane is combined with Garenoxacin.Approved, Investigational, Withdrawn
GitoformateGitoformate may decrease the cardiotoxic activities of Garenoxacin.Experimental
GuacetisalGuacetisal may increase the neuroexcitatory activities of Garenoxacin.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Halcinonide is combined with Garenoxacin.Approved, Investigational, Withdrawn
HE3286The risk or severity of adverse effects can be increased when HE3286 is combined with Garenoxacin.Investigational
HigenamineHigenamine may increase the neuroexcitatory activities of Garenoxacin.Investigational
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Garenoxacin.Approved, Vet Approved
HydrotalciteHydrotalcite can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Investigational
IbuprofenIbuprofen may increase the neuroexcitatory activities of Garenoxacin.Approved
IbuproxamIbuproxam may increase the neuroexcitatory activities of Garenoxacin.Withdrawn
IcatibantIcatibant may increase the neuroexcitatory activities of Garenoxacin.Approved
Imidazole salicylateImidazole salicylate may increase the neuroexcitatory activities of Garenoxacin.Experimental
IndobufenIndobufen may increase the neuroexcitatory activities of Garenoxacin.Investigational
IndomethacinIndomethacin may increase the neuroexcitatory activities of Garenoxacin.Approved, Investigational
IndoprofenIndoprofen may increase the neuroexcitatory activities of Garenoxacin.Withdrawn
IsoxicamIsoxicam may increase the neuroexcitatory activities of Garenoxacin.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Istaroxime is combined with Garenoxacin.Investigational
KebuzoneKebuzone may increase the neuroexcitatory activities of Garenoxacin.Experimental
KetoprofenKetoprofen may increase the neuroexcitatory activities of Garenoxacin.Approved, Vet Approved
KetorolacKetorolac may increase the neuroexcitatory activities of Garenoxacin.Approved
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Garenoxacin.Experimental
Lanthanum carbonateThe serum concentration of Garenoxacin can be decreased when it is combined with Lanthanum carbonate.Approved
LeflunomideLeflunomide may increase the neuroexcitatory activities of Garenoxacin.Approved, Investigational
LisofyllineLisofylline may increase the neuroexcitatory activities of Garenoxacin.Investigational
LonazolacLonazolac may increase the neuroexcitatory activities of Garenoxacin.Experimental
LornoxicamLornoxicam may increase the neuroexcitatory activities of Garenoxacin.Approved, Investigational
LoteprednolThe risk or severity of adverse effects can be increased when Loteprednol is combined with Garenoxacin.Approved
LoxoprofenLoxoprofen may increase the neuroexcitatory activities of Garenoxacin.Approved, Investigational
LumiracoxibLumiracoxib may increase the neuroexcitatory activities of Garenoxacin.Approved, Investigational
MagaldrateMagaldrate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
Magnesium HydroxideMagnesium Hydroxide can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium peroxideMagnesium peroxide can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Magnesium salicylateMagnesium salicylate may increase the neuroexcitatory activities of Garenoxacin.Approved
Magnesium silicateMagnesium silicate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MasoprocolMasoprocol may increase the neuroexcitatory activities of Garenoxacin.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when ME-609 is combined with Garenoxacin.Investigational
Meclofenamic acidMeclofenamic acid may increase the neuroexcitatory activities of Garenoxacin.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Garenoxacin.Approved
Mefenamic acidMefenamic acid may increase the neuroexcitatory activities of Garenoxacin.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Garenoxacin.Vet Approved
MeloxicamMeloxicam may increase the neuroexcitatory activities of Garenoxacin.Approved, Vet Approved
MesalazineMesalazine may increase the neuroexcitatory activities of Garenoxacin.Approved
MetamizoleMetamizole may increase the neuroexcitatory activities of Garenoxacin.Investigational, Withdrawn
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Garenoxacin.Approved, Vet Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Garenoxacin.Experimental
MizoribineMizoribine may increase the neuroexcitatory activities of Garenoxacin.Investigational
MofebutazoneMofebutazone may increase the neuroexcitatory activities of Garenoxacin.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with Garenoxacin.Approved, Vet Approved
Mycophenolate mofetilMycophenolate mofetil may increase the neuroexcitatory activities of Garenoxacin.Approved, Investigational
Mycophenolic acidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Garenoxacin.Approved
NabumetoneNabumetone may increase the neuroexcitatory activities of Garenoxacin.Approved
NafamostatNafamostat may increase the neuroexcitatory activities of Garenoxacin.Approved, Investigational
NaftifineNaftifine may increase the neuroexcitatory activities of Garenoxacin.Approved
NaproxenNaproxen may increase the neuroexcitatory activities of Garenoxacin.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when NCX 1022 is combined with Garenoxacin.Investigational
NepafenacNepafenac may increase the neuroexcitatory activities of Garenoxacin.Approved
NifenazoneNifenazone may increase the neuroexcitatory activities of Garenoxacin.Experimental
Niflumic AcidNiflumic Acid may increase the neuroexcitatory activities of Garenoxacin.Approved
NimesulideNimesulide may increase the neuroexcitatory activities of Garenoxacin.Approved, Investigational, Withdrawn
NitroaspirinNitroaspirin may increase the neuroexcitatory activities of Garenoxacin.Investigational
OleandrinOleandrin may decrease the cardiotoxic activities of Garenoxacin.Experimental, Investigational
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Garenoxacin.Investigational
OlopatadineOlopatadine may increase the neuroexcitatory activities of Garenoxacin.Approved
OlsalazineOlsalazine may increase the neuroexcitatory activities of Garenoxacin.Approved
OrgoteinOrgotein may increase the neuroexcitatory activities of Garenoxacin.Vet Approved
OuabainOuabain may decrease the cardiotoxic activities of Garenoxacin.Approved
OxaprozinOxaprozin may increase the neuroexcitatory activities of Garenoxacin.Approved
OxyphenbutazoneOxyphenbutazone may increase the neuroexcitatory activities of Garenoxacin.Approved, Withdrawn
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Garenoxacin.Approved
ParecoxibParecoxib may increase the neuroexcitatory activities of Garenoxacin.Approved
ParthenolideParthenolide may increase the neuroexcitatory activities of Garenoxacin.Investigational
PeruvosidePeruvoside may decrease the cardiotoxic activities of Garenoxacin.Experimental
PhenindioneGarenoxacin may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonGarenoxacin may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazonePhenylbutazone may increase the neuroexcitatory activities of Garenoxacin.Approved, Vet Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Garenoxacin.Approved
PimecrolimusPimecrolimus may increase the neuroexcitatory activities of Garenoxacin.Approved, Investigational
PirfenidonePirfenidone may increase the neuroexcitatory activities of Garenoxacin.Approved, Investigational
PiroxicamPiroxicam may increase the neuroexcitatory activities of Garenoxacin.Approved, Investigational
PirprofenPirprofen may increase the neuroexcitatory activities of Garenoxacin.Experimental
PranoprofenPranoprofen may increase the neuroexcitatory activities of Garenoxacin.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Garenoxacin.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Garenoxacin.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Garenoxacin.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Garenoxacin.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Garenoxacin.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Garenoxacin.Experimental, Investigational
ProbenecidThe serum concentration of Garenoxacin can be increased when it is combined with Probenecid.Approved
ProglumetacinProglumetacin may increase the neuroexcitatory activities of Garenoxacin.Experimental
PropacetamolPropacetamol may increase the neuroexcitatory activities of Garenoxacin.Approved, Investigational
PropyphenazonePropyphenazone may increase the neuroexcitatory activities of Garenoxacin.Experimental
ProquazoneProquazone may increase the neuroexcitatory activities of Garenoxacin.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Garenoxacin.Experimental
PTC299PTC299 may increase the neuroexcitatory activities of Garenoxacin.Investigational
QuinaprilThe serum concentration of Garenoxacin can be decreased when it is combined with Quinapril.Approved, Investigational
ResveratrolResveratrol may increase the neuroexcitatory activities of Garenoxacin.Approved, Experimental, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Garenoxacin.Approved
RofecoxibRofecoxib may increase the neuroexcitatory activities of Garenoxacin.Investigational, Withdrawn
SalicylamideSalicylamide may increase the neuroexcitatory activities of Garenoxacin.Approved
Salicylic acidSalicylic acid may increase the neuroexcitatory activities of Garenoxacin.Approved, Vet Approved
SalsalateSalsalate may increase the neuroexcitatory activities of Garenoxacin.Approved
SemapimodSemapimod may increase the neuroexcitatory activities of Garenoxacin.Investigational
SeratrodastSeratrodast may increase the neuroexcitatory activities of Garenoxacin.Approved
SerrapeptaseSerrapeptase may increase the neuroexcitatory activities of Garenoxacin.Investigational
SevelamerSevelamer can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Sodium bicarbonateSodium bicarbonate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SRT501SRT501 may increase the neuroexcitatory activities of Garenoxacin.Investigational
Strontium ranelateThe serum concentration of Garenoxacin can be decreased when it is combined with Strontium ranelate.Approved, Withdrawn
SucralfateThe serum concentration of Garenoxacin can be decreased when it is combined with Sucralfate.Approved
SulfasalazineSulfasalazine may increase the neuroexcitatory activities of Garenoxacin.Approved
SulindacSulindac may increase the neuroexcitatory activities of Garenoxacin.Approved
SuprofenSuprofen may increase the neuroexcitatory activities of Garenoxacin.Approved, Withdrawn
SuxibuzoneSuxibuzone may increase the neuroexcitatory activities of Garenoxacin.Experimental
TarenflurbilTarenflurbil may increase the neuroexcitatory activities of Garenoxacin.Investigational
TenidapTenidap may increase the neuroexcitatory activities of Garenoxacin.Experimental
TenoxicamTenoxicam may increase the neuroexcitatory activities of Garenoxacin.Approved
TepoxalinTepoxalin may increase the neuroexcitatory activities of Garenoxacin.Vet Approved
TeriflunomideTeriflunomide may increase the neuroexcitatory activities of Garenoxacin.Approved
Tiaprofenic acidTiaprofenic acid may increase the neuroexcitatory activities of Garenoxacin.Approved
TinoridineTinoridine may increase the neuroexcitatory activities of Garenoxacin.Investigational
TioclomarolGarenoxacin may increase the anticoagulant activities of Tioclomarol.Experimental
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Garenoxacin.Approved, Withdrawn
Tolfenamic AcidTolfenamic Acid may increase the neuroexcitatory activities of Garenoxacin.Approved
TolmetinTolmetin may increase the neuroexcitatory activities of Garenoxacin.Approved
TranilastTranilast may increase the neuroexcitatory activities of Garenoxacin.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Garenoxacin.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Garenoxacin.Approved, Vet Approved
TribenosideTribenoside may increase the neuroexcitatory activities of Garenoxacin.Experimental
TriptolideTriptolide may increase the neuroexcitatory activities of Garenoxacin.Investigational
TromethamineTromethamine can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
UlobetasolThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Garenoxacin.Approved
ValdecoxibValdecoxib may increase the neuroexcitatory activities of Garenoxacin.Investigational, Withdrawn
VareniclineThe serum concentration of Varenicline can be increased when it is combined with Garenoxacin.Approved, Investigational
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Garenoxacin.Approved
WarfarinGarenoxacin may increase the anticoagulant activities of Warfarin.Approved
ZaltoprofenZaltoprofen may increase the neuroexcitatory activities of Garenoxacin.Approved, Investigational
ZileutonZileuton may increase the neuroexcitatory activities of Garenoxacin.Approved, Investigational, Withdrawn
ZomepiracZomepirac may increase the neuroexcitatory activities of Garenoxacin.Withdrawn
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
110579
ChEBI
131716
ChEMBL
CHEMBL215303
Wikipedia
Garenoxacin
ATC Codes
J01MA19 — Garenoxacin

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0232 mg/mLALOGPS
logP1.71ALOGPS
logP1.62ChemAxon
logS-4.3ALOGPS
pKa (Strongest Acidic)6.05ChemAxon
pKa (Strongest Basic)8.88ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area78.87 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity110.37 m3·mol-1ChemAxon
Polarizability42.39 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as quinoline carboxylic acids. These are quinolines in which the quinoline ring system is substituted by a carboxyl group at one or more positions.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Quinolines and derivatives
Sub Class
Quinoline carboxylic acids
Direct Parent
Quinoline carboxylic acids
Alternative Parents
Hydroquinolones / Hydroquinolines / Pyridinecarboxylic acids / Isoindolines / Isoindoles / Aralkylamines / Benzenoids / Vinylogous amides / Heteroaromatic compounds / Amino acids
show 10 more
Substituents
Quinoline-3-carboxylic acid / Dihydroquinolone / Dihydroquinoline / Isoindoline / Isoindole / Isoindole or derivatives / Pyridine carboxylic acid / Pyridine carboxylic acid or derivatives / Aralkylamine / Benzenoid
show 24 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on March 19, 2008 10:14 / Updated on January 05, 2018 16:02